Day: August 15, 2025

Sampo plc, stock exchange release, 15 August 2025 at 8:30 am EEST Sampo plc’s share buybacks 14 August 2025                                                                                                                 On 14 August 2025, Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI4000552500) as follows:                     Sampo plc’s share buybacks Aggregated daily volume (in number of shares) Daily weighted average price of the purchased shares* Market (MIC Code)  3,865 9.85 AQEU    110,513 9.85 CEUX  23,565 9.85 TQEX  189,452 9.85 XHELTOTAL 327,395 9.85  * rounded to two decimals                      On 6 August 2025, Sampo announced a share buyback programme of up to a maximum of EUR 200 million in compliance with the Market Abuse Regulation...

KH Group Plc Stock Exchange Release 15 August 2025 at 8:00 am EEST KH Group Plc’s Half-Year-Report 1 January–30 June 2025 KH-Koneet’s profitability declined – NRG performed well, orderbook at record-high level This is the summary of the Half-Year Report for January–June 2025. The full Half-Year Report is attached to this release and is also available on the company’s website at www.khgroup.com. KH Group, April-June 2025 Net sales amounted to EUR 54.2 (52.2) million. Comparable operating profit was EUR 0.8 (2.4) million. Operating profit was EUR 0.5 (2.1) million Net profit for the period from continuing operations was EUR -0.6 (0.6) million. Earnings per share from continuing operations were EUR -0.01 (0.01).KH Group January–June 2025 Net sales amounted to EUR 95.9 (92.5) million. Comparable operating profit was EUR 1.0 (2.3)...

Ad hoc announcement pursuant to Art. 53 LRA Pratteln, Switzerland, 15 August, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces that by mutual agreement the Company and Highbridge Capital Management, LLC (Highbridge) have decided to extend the maturity date of the existing CHF 7 million private convertible bond, that has a strike price of CHF 10.00, to 30th September 2025. About SantheraSanthera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular diseases with high unmet medical need. The Company has an exclusive license from ReveraGen for all indications worldwide to AGAMREE® (vamorolone), a dissociative steroid with novel mode of action, which was investigated in a pivotal study in patients with Duchenne muscular dystrophy...

Propanc common stock expected to begin trading on Nasdaq under the symbol PPCB MELBOURNE, Australia, Aug. 14, 2025 (GLOBE NEWSWIRE) — Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced the pricing of an underwritten public offering of 1,000,000 shares of its common stock, par value $0.001 per share, at a price of $4.00 per share. The offering is expected to yield approximately $4 million in gross proceeds before offering expenses and underwriting discounts and commissions. Propanc intends to use the net proceeds from the offering for its working capital and general business purposes. In connection with the offering, the Company has also granted the underwriter a 45-day option...

HAMPTON, N.H., Aug. 14, 2025 (GLOBE NEWSWIRE) — Unitil Corporation (NYSE: UTL) (unitil.com) (the “Company”) today announced that it has priced its previously announced public offering of 1,393,355 shares of its common stock at a price of $46.65 per share. The offering is expected to close on August 18, 2025, subject to customary closing conditions. The Company has granted the underwriters of the offering an option to purchase up to an additional 209,003 shares of common stock at the public offering price, less underwriting discounts and commissions. The Company intends to use the net proceeds from the offering to (i) make equity capital contributions to its regulated utility subsidiaries, (ii) to repay indebtedness outstanding under its Second Amendment to Third Amended and Restated Credit Agreement dated January 29, 2025 among...

Breakthrough Protein Phosphatase 2A inhibitor LB-100 Targets Ovarian Clear Cell Carcinoma, Advanced Soft Tissue Sarcoma, and MSS Metastatic Colon Cancer 24/7 Market News Issues Corrected Information on Previously issued Press Release with same title DENVER, Aug. 14, 2025 (GLOBE NEWSWIRE) — 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, spotlights LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage pharmaceutical company focused on developing novel cancer therapies by targeting the modulation of key cellular pathways. 2H 2025 is shaping up to be a defining year for LIXTE. With a focus on its lead compound LB-100, a first-in-class small molecule inhibitor of protein phosphatase 2A (PP2A), a master regulator of cell signaling and...